Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (311-320 of 491) with videos related to

Pageof 50
Sort By:
The Lancet. Oncology|December 14, 2011
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohortsHeikki Joensuu, Aki Vehtari, Jaakko Riihimäki, et al.
Annals of Surgery|September 27, 2023
New Sarculator Prognostic Nomograms for Patients With Primary Retroperitoneal Sarcoma: Case Volume Does MatterDario Callegaro, Francesco Barretta, Chandrajit P Raut, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective studyPiotr Rutkowski, Alice Indini, Matilde De Luca, et al.
European Journal of Cancer (Oxford, England : 1990)|January 19, 2021
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trialRobin L Jones, César Serrano, Margaret von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialCeleste Lebbé, Nicolas Meyer, Laurent Mortier, et al.
Cancers|June 22, 2023
The Current Treatment Trends and Survival Patterns in Melanoma Patients with Positive Sentinel Lymph Node Biopsy (SLNB): A Multicenter Nationwide StudyMarcin Ziętek, Paweł Teterycz, Jędrzej Wierzbicki, et al.
Clinical Sarcoma Research|September 22, 2016
Current status and unanswered questions on the use of Denosumab in giant cell tumor of boneCzar Louie Gaston, Robert J Grimer, Michael Parry, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trialsAxel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.
Cancers|May 14, 2022
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma PatientsPaweł Rogala, Anna M Czarnecka, Bożena Cybulska-Stopa, et al.
The Lancet. Respiratory Medicine|April 20, 2018
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trialPatrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, et al.
Pageof 50

Showing results (311-320 of 491) with videos related to

Sort By:
Pageof 50
The Lancet. Oncology|December 14, 2011
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohortsHeikki Joensuu, Aki Vehtari, Jaakko Riihimäki, et al.
Annals of Surgery|September 27, 2023
New Sarculator Prognostic Nomograms for Patients With Primary Retroperitoneal Sarcoma: Case Volume Does MatterDario Callegaro, Francesco Barretta, Chandrajit P Raut, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective studyPiotr Rutkowski, Alice Indini, Matilde De Luca, et al.
European Journal of Cancer (Oxford, England : 1990)|January 19, 2021
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trialRobin L Jones, César Serrano, Margaret von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialCeleste Lebbé, Nicolas Meyer, Laurent Mortier, et al.
Cancers|June 22, 2023
The Current Treatment Trends and Survival Patterns in Melanoma Patients with Positive Sentinel Lymph Node Biopsy (SLNB): A Multicenter Nationwide StudyMarcin Ziętek, Paweł Teterycz, Jędrzej Wierzbicki, et al.
Clinical Sarcoma Research|September 22, 2016
Current status and unanswered questions on the use of Denosumab in giant cell tumor of boneCzar Louie Gaston, Robert J Grimer, Michael Parry, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trialsAxel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.
Cancers|May 14, 2022
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma PatientsPaweł Rogala, Anna M Czarnecka, Bożena Cybulska-Stopa, et al.
The Lancet. Respiratory Medicine|April 20, 2018
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trialPatrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, et al.
Pageof 50